We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.
- Authors
Kendler, D L; McClung, M R; Freemantle, N; Lillestol, M; Moffett, A H; Borenstein, J; Satram-Hoang, S; Yang, Y-C; Kaur, P; Macarios, D; Siddhanti, S; DAPS Investigators
- Abstract
In this study, 250 women with osteoporosis were randomized to 12 months with subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg once weekly, then crossed over to the other treatment. The primary endpoint, treatment adherence at 12 months, was 76.6% for alendronate and 87.3% for denosumab.
- Publication
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Vol 22, Issue 6, p1725
- ISSN
1433-2965
- Publication type
Journal Article
- DOI
10.1007/s00198-010-1378-z